000250 - Samchundang Pharm

000250 Summary

Biopharma

Stock Price & Overview

₩157,000 +1,600 (+1.03%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩157,000 ≈ US$112 · Market cap ₩3.7tn (≈ $2.6bn)

000250 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	231.8	210.9	192.7	177.3	167.3	166.9	186.6	160.0	160.6	147.4	132.1
Cost of Revenue	122.4	111.3	95.7	87.3	84.2	72.9	75.9	76.8	75.8	68.3	60.1
Gross Profit	109.4	99.7	97.0	90.0	83.1	94.0	110.7	83.2	84.8	79.1	72.0
Selling, General & Administrative	100.9	97.0	87.4	77.8	98.4	88.5	85.4	67.7	60.8	54.7	51.2
Operating Income	8.5	2.6	9.6	12.2	-15.3	5.5	25.2	15.5	24.0	24.4	20.8
Finance Income	4.2	5.9	2.8	2.3	1.5	1.8	2.1	1.7	1.4	1.2	1.1
Finance Costs	1.4	0.6	2.9	2.9	1.9	0.9	0.9	0.3	0.3	—	—
Pretax Income	12.5	11.0	-4.5	8.9	-19.5	16.6	19.3	14.5	24.1	22.7	20.8
Income Tax Expense	0.5	16.1	-0.4	0.1	-9.2	9.1	-0.3	-0.1	3.6	7.0	3.0
Net Income	12.0	-5.1	-4.2	8.8	-10.4	7.5	19.6	14.6	20.5	15.6	17.9
Total Comprehensive Income	12.2	-5.4	-5.6	9.4	-6.4	7.9	19.5	14.1	26.9	15.8	16.0

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	561.2	519.8	408.0	373.3	343.9	317.1	290.2	261.2	230.1	205.1	184.3
Current Assets	241.8	242.5	163.9	157.7	168.9	166.5	162.5	142.3	131.2	116.6	98.9
Cash & Cash Equivalents	95.9	105.6	40.4	22.1	49.1	58.9	60.3	51.5	61.9	48.6	34.9
Inventories	52.6	38.2	35.3	31.9	27.9	25.3	23.0	22.4	21.8	19.2	17.7
Trade Receivables	55.3	58.1	34.4	37.9	34.2	31.6	38.5	36.8	38.9	38.3	32.4
Non-current Assets	319.5	277.2	244.1	215.5	175.0	150.6	127.7	118.9	98.9	88.5	85.3
Property, Plant & Equipment	143.1	103.6	90.0	87.2	74.1	63.3	57.3	60.7	55.2	57.9	59.3
Intangible Assets	129.8	122.2	96.3	80.8	46.4	32.9	30.2	21.1	15.0	13.1	8.6
Total Liabilities	197.6	170.4	109.6	127.6	93.6	59.4	67.0	55.4	36.4	34.1	29.9
Current Liabilities	106.6	93.4	58.0	38.2	54.0	23.7	45.2	38.4	23.7	26.1	21.7
Non-current Liabilities	91.1	76.9	51.6	89.5	39.6	35.7	21.7	17.0	12.7	8.0	8.2
Total Equity	363.6	349.4	298.5	245.6	250.3	257.7	223.2	205.8	193.8	171.0	154.3
Share Capital	11.7	11.7	11.7	11.4	11.4	11.4	11.1	11.1	11.1	11.0	10.6
Retained Earnings	96.0	95.5	106.0	112.1	112.5	127.0	124.8	115.7	101.1	91.1	80.7

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	9.8	21.8	23.4	13.3	-7.7	3.2	30.6	25.0	26.1	17.8	17.3
Cash from Investing Activities	-42.4	-23.2	-8.4	-53.9	-30.1	-19.2	-19.3	-50.3	-9.4	-7.2	-13.8
Purchase of Property, Plant & Equipment	46.1	17.0	6.8	16.5	14.9	8.7	6.6	11.6	3.3	4.1	8.7
Cash from Financing Activities	22.8	65.8	3.4	13.3	27.7	14.7	-2.4	14.8	-3.3	3.2	-1.9
Dividends Paid	4.7	0.9	0.9	1.0	1.0	2.1	2.1	2.1	2.1	2.0	2.5
Net Change in Cash	-9.6	65.2	18.3	-27.0	-9.8	-1.3	8.8	-10.4	13.3	13.8	1.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	70.7	64.9	66.3	58.0	56.9	50.6	55.2	52.4	54.9	48.5
Cost of Revenue	38.1	33.0	34.7	30.9	31.0	25.8	29.3	28.4	29.2	24.4
Gross Profit	32.7	31.9	31.6	27.1	25.9	24.8	25.9	24.0	25.7	24.0
Selling, General & Administrative	29.2	26.4	26.1	23.7	27.0	24.1	26.5	24.8	23.6	22.2
Operating Income	3.4	5.4	5.4	3.4	-1.1	0.7	-0.5	-0.8	2.1	1.9
Finance Income	0.5	2.3	1.1	1.9	0.4	1.8	2.3	1.4	1.2	1.0
Finance Costs	-0.4	1.0	-0.2	0.6	1.4	0.6	-0.7	1.1	-0.4	0.6
Pretax Income	8.6	8.4	7.4	5.3	-1.7	1.6	3.9	-0.0	4.4	2.8
Income Tax Expense	2.4	1.5	-0.5	0.8	-0.1	0.3	12.8	0.3	2.6	0.5
Net Income	6.2	6.9	7.9	4.5	-1.6	1.3	-8.9	-0.3	1.8	2.3
Total Comprehensive Income	6.3	7.0	8.2	4.4	-1.8	1.4	-7.2	-0.3	-0.4	2.4

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	575.4	573.1	561.2	530.0	486.2	493.8	519.8	493.3	491.4	413.5
Current Assets	231.6	240.3	241.8	221.3	201.2	212.8	242.5	239.0	245.5	164.5
Cash & Cash Equivalents	63.0	84.2	95.9	103.1	81.5	82.8	105.6	134.0	102.0	49.0
Inventories	58.0	48.7	52.6	47.8	46.8	41.3	38.2	40.1	39.9	38.8
Trade Receivables	65.5	67.2	55.3	46.5	39.8	39.6	58.1	36.0	71.6	34.2
Non-current Assets	343.8	332.8	319.5	308.6	285.1	281.0	277.2	254.2	245.9	249.0
Property, Plant & Equipment	152.7	150.4	143.1	132.2	113.2	104.6	103.6	96.5	87.6	88.1
Intangible Assets	147.3	135.9	129.8	127.5	121.0	125.0	122.2	109.2	105.6	100.6
Total Liabilities	174.6	178.6	197.6	175.0	142.3	147.5	170.4	136.9	134.9	113.4
Current Liabilities	104.7	110.0	106.6	89.2	68.4	70.3	93.4	58.3	74.2	61.1
Non-current Liabilities	69.9	68.7	91.1	85.7	74.0	77.3	76.9	78.6	60.7	52.2
Total Equity	400.8	394.5	363.6	355.0	343.9	346.2	349.4	356.4	356.5	300.2
Share Capital	11.7	11.7	11.7	11.7	11.7	11.7	11.7	11.7	11.7	11.7
Retained Earnings	104.4	100.2	96.0	90.3	87.9	91.2	95.5	104.4	105.5	107.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	12.0	-9.7	9.6	14.1	-15.2	1.2	5.3	4.4	9.9	2.2
Cash from Investing Activities	-34.5	-12.5	-16.0	-21.9	15.5	-19.9	-23.8	-11.8	6.1	6.3
Purchase of Property, Plant & Equipment	10.1	13.2	12.6	20.8	5.3	7.4	2.1	10.1	3.0	1.8
Cash from Financing Activities	1.9	9.4	-1.3	28.5	0.1	-4.6	-10.6	39.7	36.9	-0.3
Dividends Paid	1.2	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.9	0.0
Net Change in Cash	-21.2	-11.7	-7.2	21.7	-1.4	-22.8	-28.4	32.0	53.0	8.6

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

000250 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	231.8	+9.9%	+9.3%	+6.8%	+5.8%
Operating income	8.5	+220.5%	-11.5%	+8.9%	-8.6%
Net income	12.0	—	+10.9%	+9.9%	-3.9%
EPS	₩513	—	+10.9%	+9.9%	-3.9%
Operating cash flow	9.8	-55.0%	-9.7%	+24.7%	-5.6%
Shareholders' equity	363.6	+4.1%	+14.0%	+7.1%	+8.9%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

000250 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	47.2%	47.3%	50.3%	50.7%	49.7%	56.3%
Operating margin	3.7%	1.3%	5.0%	6.9%	-9.1%	3.3%
Net margin	5.2%	-2.4%	-2.2%	5.0%	-6.2%	4.5%
Return on equity	3.4%	-1.6%	-1.5%	3.6%	-4.1%	3.1%
Return on assets	2.2%	-1.1%	-1.1%	2.5%	-3.1%	2.5%
Operating cash flow / revenue	4.2%	10.3%	12.2%	7.5%	-4.6%	1.9%
Capex / revenue	19.9%	8.1%	3.5%	9.3%	8.9%	5.2%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 000250

Symbol	Last Price
000100Yuhan Corporation	₩81,400 +0.0%
028300HLB Co., Ltd.	₩33,750 +2.9%
298380ABL Bio Inc.	₩71,400 +5.6%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.